Brucein D augments the chemosensitivity of gemcitabine in pancreatic cancer via inhibiting the Nrf2 pathway

Abstract Background Gemcitabine (GEM) is the first-line chemotherapeutic drug used to treat pancreatic ductal adenocarcinoma carcinoma (PDAC), but chemoresistance is often encountered clinically. Nrf2, an oxidative stress responsive transcription factor, is an important contributor to chemoresistanc...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Juan Zhang, Hong-Xi Xu, William Chi Shing Cho, Wah Cheuk, Yang Li, Qiong-Hui Huang, Wen Yang, Yan-Fang Xian, Zhi-Xiu Lin
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2022-03-01
Edice:	Journal of Experimental & Clinical Cancer Research
Témata:	Brucein D Gemcitabine Chemosensitivity Pancreatic cancer Nrf2
On-line přístup:	https://doi.org/10.1186/s13046-022-02270-z
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!